Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Have participated in Study JAIW (NCT03435081), and meet specific completion requirements for that study, and do not meet any of the following Exclusions:~* Have significant uncontrolled cerebro-cardiovascular (e.g., myocardial infarction \[MI\], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the participant if investigational product continues to be administered.~* Have a known hypersensitivity to baricitinib or any component of this investigational product.~* Had investigational product permanently discontinued at any time during a previous baricitinib study, except for participants who had investigational product discontinued during originating study because of rescue with an oral systemic AD therapy (e.g., corticosteroid, cyclosporine, methotrexate).~* Had temporary investigational product interruption continue at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study.~* Pregnant or breastfeeding~OR~• Have not participated in a Study JAIW (NCT03435081) and satisfy the following criteria:~Inclusion Criteria:~* Have a diagnosis of atopic dermatitis (AD) at least 12 months before screening.~* Have moderate to severe AD, including all of the following:~  * EASI score ≥16~ * IGA score of ≥3~ * 10%- 50% BSA involvement~* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.~* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments)~* Agree to use emollients daily.~Exclusion Criteria:~* Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.~* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.~* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.~* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).~* Have been treated with the following therapies:~  * monoclonal antibody for less than 5 half-lives before randomization~ * received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks before randomization~ * received any parenteral corticosteroid administered by intramuscular or intravenous injection within 6 weeks of planned randomization or are anticipated to require parenteral injection of corticosteroids during the study~ * have had an intra-articular corticosteroid injection within 6 weeks of planned randomization~ * probenecid at the time of randomization that cannot be discontinued for the duration of the study~* Have high blood pressure characterized by a repeated systolic blood pressure \>160 millimeters of mercury (mm Hg) or diastolic blood pressure \>100 mm Hg.~* Have had major surgery within the past eight weeks or are planning major surgery during the study.~* Have experienced any of the following within 12 weeks of screening: myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.~* Have a history of venous thromboembolic event (VTE), or are considered at high risk for VTE.~* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.~* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.~* Have specific laboratory abnormalities.~* Have received certain treatments that are contraindicated.~* Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/Baricitinib 2-milligram (mg) (Type: EXPERIMENTAL): Open-label 2 mg baricitinib administered orally once daily (QD) to participants who randomized to placebo in the originating study (JAIW).
- Baricitinib 1-mg/Baricitinib 2-mg (Type: EXPERIMENTAL): Open-label 2 mg baricitinib administered orally QD to participants who randomized to 1 mg baricitinib in the originating study (JAIW).
- Baricitinib 2-mg/Baricitinib 2-mg (Type: EXPERIMENTAL): Open-label 2 mg baricitinib administered orally QD to participants who randomized to 2 mg baricitinib in the originating study (JAIW).
- Baricitinib 2-mg Open-Label Addendum (Type: EXPERIMENTAL): Participants were directly enrolled to receive open-label 2 mg baricitinib orally QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy